List of Publications

  • Chapman, D., I. Morad, G. Kaufmann, M. J. Gait, L. Jorissen, and L. Snyder. 1988. Nucleotide and deduced amino acid sequence of stp: the bacteriophage T4 anticodon nuclease gene. J. Mol. Biol. 199:373-377.
  • Amitsur, M., I. Morad, and G. Kaufmann. 1989. In vitro reconstitution of anticodon nuclease from components encoded by phage T4 and Escherichia coli CTr5X. EMBO J. 8:2411-2415.
  • Kaufmann, G., M. Amitsur, D. Chapman, M. J. Gait, R. Levitz, L. Jorissen, I. Morad, and L. Snider. 1989. Host tRNA reprocessing: a phage T4-system of RNA-splicing mediated by protein enzymes. in (T.R. Cech ed.) Molecular Biology of RNA. UCLA symp. Mol. Biol. New Series. Alan Liss, Inc. New York. Vol. 94 pp. 281-287.
  • Amitsur, M., I. Morad, D. Chapman-Shimshoni, and G. Kaufmann. 1992. Hsd restriction modification proteins partake in latent anticodon nuclease. EMBO J. 11:3129-3134.
  • Morad, I., D. Chapman-Shimshoni, M. Amitsur and G. Kaufmann. 1993. Functional expression and properties of the tRNALys-specific core anticodon nuclease encoded by Escherichia coli prrC. J. Biol. Chem. 268:26842-26849.
  • M. Penner, I., Morad, L., Snyder, and G. Kaufmann. 1995. Phage T4-coded Stp: double-edjed effector of coupled DNA and tRNA-restriction systems. J. Mol. Biol. 249:857-868.
  • Shterman, N., O. Elroy-Stein, I. Morad, M. Amitsur and G. Kaufmann. 1995. Cleavage of the HIV replication primer tRNALys,3 in human cells expressing bacterial anticodon nuclease. NAR 23:1744-1749.
  • Meidler, R., I. Morad, M. Amitsur, H., Hachiro, and G. Kaufmann. 1999. Detection of anticodon nuclease residues involved in tRNALys cleavage specificity. J. Mol. Biol. 287:499-510.
  • Morad, I., H. Itzhaki. 2019. MuTaTo-A novel concept for curing cancer. Pharmafile Spring issue. pp.16-19.
  • Morad, I., H. Itzhaki. 2020. MuTaTo-A novel concept for curing cancer. Journal of Cancer Therapy, 11:55-73.

Ilan Morad, PH.D.

Curriculum Vitae


Research Scientist & CEO at AEBi

Researcher at Peptor Ltd.

Harvard University

Molecular Biology
  • Postdoctoral fellow - Biological Chemistry and Molecular Pharmacology with Prof. Kevin Struhl

Tel Aviv University

Molecular Biology and Biochemistry
  • Postdoctoral fellow - Biochemistry with Prof.Gabriel Kaufman and Prof. Amnon Hizzi

Tel Aviv University

Molecular Biology, Biochemistry and Organic Chemistry
  • Ph.D. Student and Organic Chemistry teaching assistant - Biochemistry with Prof. Gabriel Kaufman

Tel Aviv University

Molecular Biology, Biochemistry and Analytical Chemistry
  • M.Sc. Student and Analytical Chemistry Instructor - Biochemistry with Prof. Gabriel Kaufman

Tel Aviv University

  • B.Sc. - Chemistry

Practicing Molecular Biology and Biochemistry since 1984.

Expert in gene cloning, protein engineering, purification and characterization, and drug discovery.

The last two decades were dedicated to the founding and management of AEBi.

There is no clinical tryout at the moment of MuTaTo in Israel or outside of Israel.

Contact us at

Contact Us

    Our team are research scientists (Ph.D.) and are not attending Dr.

    We are working now for the 20th year entering our 21th year of R&D effort (in June 2022).

    We don’t have a Clinique and we can not advise nor refer to any specific case.

    We initially intend to target: lung, colon, head & neck cancers.

    The treatment, in any case, has to be individually adapted to the patient.

    We are a small team and have an influx of e-mail.

    We try to answer at least initial emails but can not promise it.

    This website may contain certain statements, estimations, projections, assessments and other information with respect to the anticipated future performance of the Company and/or its market and involve risks and uncertainties. Actual results or future business decisions of the Company may differ materially from any expectations, projections or predictions made or implicated in statements made in this website. While the Company believes that the information contained herein is accurate, it expressly disclaims any and all liability for representations or warranties, expressed or implied, contained in, or for omissions from, this website or any other communication transmitted or made available herein. Any prospective website user acknowledges his/her responsibility to perform a due diligence review prior to consummating a transaction with the Company. Included in this website are certain declarations by the Company with respect to its anticipated future performance. These declarations are based on estimates and assumptions by the Company that are subject to economic and competitive uncertainties beyond the control of the Company. The Company does not provide representation or warranty with regard to the declarations and there can be no assurance that the future results will be realized or that actual results will not be significantly different from those projected. The Company is not obligated to update or revise any future declarations. The Company and its respective affiliates, directors, officers, employees, consultants and representatives expressly disclaim any and all liability relating to or resulting from the utilization of any information contented in this website. The Company does not have any obligation to provide with access to additional information.